Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E7.18 EPS (ttm)11.93 Insider Own0.40% Shs Outstand1.49B Perf Week-15.01%
Market Cap127.51B Forward P/E6.89 EPS next Y12.42 Insider Trans-19.35% Shs Float1.35B Perf Month-10.43%
Income18.11B PEG5.73 EPS next Q3.01 Inst Own85.60% Short Float1.98% Perf Quarter-0.44%
Sales32.64B P/S3.91 EPS this Y62.00% Inst Trans-0.12% Short Ratio2.26 Perf Half Y-21.18%
Book/sh10.14 P/B8.44 EPS next Y1.76% ROA36.60% Target Price111.48 Perf Year-15.49%
Cash/sh- P/C- EPS next 5Y1.25% ROE104.70% 52W Range81.50 - 121.77 Perf YTD-15.00%
Dividend1.72 P/FCF- EPS past 5Y48.30% ROI45.80% 52W High-29.29% Beta1.07
Dividend %2.01% Quick Ratio2.50 Sales past 5Y32.60% Gross Margin87.70% 52W Low5.65% ATR2.43
Employees8000 Current Ratio2.70 Sales Q/Q2.60% Oper. Margin65.80% RSI (14)30.27 Volatility3.37% 2.14%
OptionableYes Debt/Eq0.00 EPS Q/Q-8.60% Profit Margin53.10% Rel Volume0.77 Prev Close85.60
ShortableYes LT Debt/Eq0.00 EarningsApr 28 AMC Payout10.70% Avg Volume11.79M Price86.10
Recom2.10 SMA20-10.88% SMA50-7.36% SMA200-13.61% Volume3,573,765 Change0.58%
Apr-29-16Reiterated UBS Buy $130 → $118
Apr-29-16Downgrade Maxim Group Buy → Hold
Mar-16-16Reiterated Leerink Partners Outperform $130 → $127
Feb-25-16Initiated Citigroup Buy $110
Feb-12-16Reiterated Maxim Group Buy $137 → $115
Feb-03-16Reiterated RBC Capital Mkts Outperform $130 → $120
Feb-03-16Reiterated Piper Jaffray Overweight $134 → $114
Feb-03-16Reiterated Oppenheimer Outperform $124 → $120
Feb-03-16Reiterated Barclays Overweight $130 → $115
Feb-03-16Initiated Standpoint Research Buy $110
Jan-20-16Initiated Credit Suisse Outperform $125
Jan-15-16Upgrade BofA/Merrill Underperform → Neutral $107
Oct-28-15Reiterated Maxim Group Buy $129 → $137
Oct-20-15Reiterated Oppenheimer Outperform $120 → $124
Oct-02-15Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-09-15Initiated Jefferies Hold
Jul-29-15Reiterated RBC Capital Mkts Outperform $120 → $130
Jul-29-15Reiterated Piper Jaffray Overweight $131 → $134
Jul-29-15Reiterated Oppenheimer Outperform $86 → $120
Jul-29-15Reiterated Needham Buy $120 → $125
May-05-16 09:30AM  The Zacks Analyst Blog Highlights: Amgen, Gilead, Celgene, Medivation and Biogen Zacks
06:51AM  Pro's top value plays CNBC
May-04-16 03:41PM  Better Buy: Gilead Sciences vs. Biogen at Motley Fool
01:11PM  Biotech Stock Roundup: Amgen Impresses, Gilead Disappoints in Q1, Biogen to Spin Off Hemophilia Zacks
10:05AM  Gilead Sciences: Feeling the Competitive Burn? at Barrons.com
08:04AM  3 Dirt-Cheap Biotech Stocks To Buy at Motley Fool
May-03-16 02:22PM  5 Data Points Wall Street Is Anxiously Awaiting in Merck's Q1 Report at Motley Fool
02:17PM  Stocks stumble as traders seek safety Yahoo Finance
02:04PM  ETFs with exposure to Gilead Sciences, Inc. : May 3, 2016 at Capital Cube
01:35PM  Can Gilead Shares Still Really Rise to $150? at 24/7 Wall St.
12:09PM  This New Stock Market Trend Is Catching Investors By Surprise (but It Shouldn't) at Motley Fool
10:49AM  Biogen's Hemophilia Spin: Prelude to a Takeover? at Barrons.com
09:07AM  Gilead Sciences Is Cannibalizing Its Own Sales, and Management Loves It at Motley Fool
08:59AM  How to Trade 5 Biotech Stocks After a Fall -- Plus Jim Cramer's Take at TheStreet
12:34AM  Judge Allows More Evidence in Patent Dispute After Gilead Says Merck Attorney Lied at The Wall Street Journal
May-02-16 07:01PM  Cramer: Get Ready for More Downgrades for Tech and Biotech at TheStreet
06:50PM  Cramer: Apple -- Stay or Go? at TheStreet
03:22PM  Biotech ETFs Sink on Mixed Q1 Results Zacks
01:23PM  Good News: Gilead Sciences Discounted Its Drugs Again at Motley Fool
12:38PM  Gilead: What's Your Long Term Thesis? Yahoo Finance Contributors
11:46AM  Don't Give Up on Gilead Following a Weak Q1 at TheStreet
11:02AM  Gilead Sciences, Inc. :GILD-US: Earnings Analysis: Q1, 2016 By the Numbers at Capital Cube
10:36AM  Gilead Stock Punished on Q1 Earnings Miss (GILD) at Investopedia
10:13AM  Gilead Sciences to Merck: Not So Fast at Barrons.com
08:49AM  Gilead Sciences, Inc. breached its 50 day moving average in a Bearish Manner : GILD-US : May 2, 2016 at Capital Cube
May-01-16 02:03PM  Does Healthcares Past Predict its Future? at Motley Fool
10:50AM  Analysts Make Major Changes to Top Biotech Ratings at 24/7 Wall St.
Apr-30-16 12:03PM  3 Key Pipeline Developments for Gilead Investors to Watch at Motley Fool
12:20AM  [$$] Gilead: The Deals Elephant Is in the Room at The Wall Street Journal
Apr-29-16 08:27PM  Gilead Judge Re-Opens Case Amid Claim Merck Scientist Lied at Bloomberg -9.06%
05:00PM  5 way to trade the mixed biotech sector CNBC
04:13PM  Amazon, LinkedIn Get PT Hikes; Baidu Upgraded, Gilead Sciences Cut at Investor's Business Daily
03:51PM  Looking for dividends CNBC
02:24PM  Maxim Cuts Gilead To Hold: Victim Of Its Own Success at Barrons.com
02:00PM  Gilead drops, brings down S&P health care sector at CNBC
01:56PM  A Typical Bad First Quarter For Biotech: Leerink at Barrons.com
01:51PM  Gilead Stock: Analyzing 5 Key Suppliers (GILD) at Investopedia
01:40PM  Gilead Sciences Takes Lumps From Wall Street After Q1 Miss at Investor's Business Daily
01:14PM  What Are Analysts Saying About Q1 At Biotech's Big 4? Amgen, Biogen, Celgene, Gilead at Forbes
12:33PM  [$$] Gilead: The Deals Elephant Is in the Room at The Wall Street Journal
12:06PM  Midday Report: Rovi Agrees to TiVo Acquisition; U.S. Stocks Slump at TheStreet
11:36AM  Gilead (GILD) Stock Plunges as Maxim Downgrades on Weak Q1 Earnings at TheStreet
11:16AM  Gilead Sciences, Inc. Reports Disappointing Q1 Harvoni Sales at Motley Fool
10:52AM  Amazon, LinkedIn, Gilead, & More: Heres Why These Stocks Are Trending Today at Insider Monkey
09:42AM  Gilead Says European CHMP Adopts Positive Opinion For Its Odefsey For Treating HIV Benzinga
09:27AM  Stocks to Watch: AK Steel, TiVo, Amazon at The Wall Street Journal
09:19AM  Gilead (GILD) Lags Q1 Earnings & Revenues, '16 View Intact Zacks
09:10AM  Top Analyst Upgrades and Downgrades: Amazon, Ford, Gilead, Level 3, Sarepta, Western Digital, Whiting Petroleum and More at 24/7 Wall St.
08:42AM  Stock Futures Slip as Consumers Save Instead of Spend at TheStreet
08:21AM  European CHMP Adopts Positive Opinion for Gileads TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for Treatment of HIV Business Wire
08:00AM  Early movers: AMZN, VRX, TIVO, TYC, DAL, VFC, MCO, NWL, BUD & more at CNBC
07:19AM  Gilead Sciences downgraded by Maxim Group Briefing.com
02:43AM  Edited Transcript of GILD earnings conference call or presentation 28-Apr-16 8:30pm GMT Thomson Reuters StreetEvents
Apr-28-16 11:28PM  Gilead Disappoints, Harvoni Sales Drop 16% Yahoo Finance Contributors
08:01PM  9 Figures That Sum Up Gilead Sciences' First Quarter at Motley Fool
06:32PM  Price pressure hits Gilead 1st qtr US hepatitis C drug sales Reuters
06:04PM  Gilead 1Q profit tumbles on slower hepatitis C drug sales AP
05:59PM  Q1 Earnings Reports Continue the Deluge: AMZN, GILD, AMGN Zacks
05:37PM  After Hours: Amazon, LinkedIn, Baidu, Expedia Soar, Gilead Flops at Investor's Business Daily
05:29PM  Gilead Sciences (GILD) Stock Slumps on Q1 Earnings, Revenue Miss Zacks
05:13PM  Amgen Legacy Drugs Drive Q1 Beat; Gilead Hep C Juggernaut Stumbles at Investor's Business Daily
05:06PM  After-hours buzz: Amazon, LinkedIn, Gilead, Expedia, Pandora & more at CNBC
04:43PM  Gilead 1st quarter hepatitis C drug sales fall short, shares dip Reuters
04:38PM  Gilead (GILD) Stock Down in After-Hours Trading on Q1 Earnings, Revenue Miss at TheStreet
04:37PM  [$$] Gilead reports drop in Hepatitis C Drug Revenue at The Wall Street Journal
04:30PM  Gilead Sciences Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:27PM  Gilead falls on earnings miss; Sales of hepatitis C drugs below estimates at CNBC
04:13PM  Gilead shares fall after company misses on revenue at MarketWatch
04:10PM  GILEAD SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib EDGAR Online
04:07PM  Gilead misses on earnings & revenue CNBC
04:07PM  Gilead Falls After Q1 Earnings, Revenue Miss at Barrons.com
04:04PM  Gileads Profit, Hepatitis C Drugs Sales Miss Estimates at Bloomberg
04:02PM  Gilead Sciences Announces Second Quarter 2016 Dividend Business Wire
04:01PM  Gilead Sciences Announces First Quarter 2016 Financial Results Business Wire
03:05PM  5 Best ROE Stocks to Beat Earnings Blues Zacks
12:00PM  Biotech Boom May Continue Through Earnings Season Benzinga
10:38AM  Gilead Sciences (GILD) Stock Retreats Ahead of Q1 Results Despite Credit Suisse's Optimism at TheStreet
09:00AM  Will Gileads Run Come to an End this Quarter? Yahoo Finance Contributors
07:07AM  Q1 2016 Gilead Sciences Inc Earnings Release - After Market Close CCBN
Apr-27-16 06:52PM  Amazon Earnings Top 5 Things You Need To Know For Thursday at Investor's Business Daily
04:07PM  Biotech Stock Roundup: Biogen Tops on Q1 Earnings, Sarepta, Catalyst Plunge on Regulatory News Zacks
03:17PM  Credit Suisse Ups Gilead Target Ahead Of Earnings at Barrons.com
02:52PM  Street Talk: LB, GILD, BLMN, & more CNBC
09:55AM  Why Gilead Should Gain On Q1 Earnings Yahoo Finance Contributors
09:05AM  4 Biotech Stocks Reporting on Apr 28: AMGN, GILD, ALXN, CELG Zacks
08:52AM  Why Gilead Sciences (GILD) Might Surprise This Earnings Season Zacks
08:10AM  Short Sellers Run for Cover From Major Biotechs at 24/7 Wall St.
Apr-26-16 02:26PM  Gilead Sciences Shows Further Upside Potential at TheStreet
11:37AM  Biotech Stock Gilead (GILD) Likely to Beat in Q1 Earnings Zacks
08:08AM  Big Biotech In The Earnings Spotlight Benzinga
Apr-25-16 10:37PM  These Are The Companies Reporting Earnings This Week Yahoo Finance Contributors
06:01PM  Can Arrowhead Do For Hep B What Gilead Sciences Did For Hep C? at Motley Fool
10:58AM  Healthcare Q1 Earnings Look Solid: ETFs to Benefit Zacks
09:00AM  5 Stocks to Watch this Week 4/25 - AAPL, CMG, FB, AMZN, GILD Yahoo Finance Contributors
08:30AM  Gilead Gets European Commission Marketing Authorization For HIV-1 Infection Drug Benzinga
07:10AM  European Commission Grants Marketing Authorization for Gileads Fixed-Dose Combination Descovy® (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV Business Wire
Apr-24-16 11:43AM  87% of Americans Want Medicare to Have This Power, but the Federal Government Disagrees at Motley Fool
Apr-23-16 03:16PM  3 Things to Watch in Gilead Sciences, Inc.'s First-Quarter Results at Motley Fool
Apr-22-16 01:23PM  3 Stocks to Buy in a Crashing Market at Motley Fool
Apr-21-16 05:00PM  Gilead Sciences to Release First Quarter 2016 Financial Results on Thursday, April 28, 2016 Business Wire
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company's products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Carter Paul RutherfordEVP Commercial OpsMay 02Option Exercise39.132,00078,25563,122May 04 04:23 PM
MARTIN JOHN CExecutive ChairmanMay 02Option Exercise16.40100,0001,639,5004,119,727May 04 02:44 PM
MILLIGAN JOHN FPresident and CEOMay 02Option Exercise16.40112,0001,836,2401,170,963May 04 02:49 PM
MARTIN JOHN CExecutive ChairmanMay 02Sale87.82100,0008,781,6944,019,727May 04 02:44 PM
MILLIGAN JOHN FPresident and CEOMay 02Sale87.71112,0009,823,9541,058,963May 04 02:49 PM
Carter Paul RutherfordEVP Commercial OpsMay 02Sale88.722,000177,44861,122May 04 04:23 PM
Alton Gregg HEVP, Corp & Med AffairsApr 19Option Exercise26.9935,874968,239177,964Apr 21 01:28 PM
Alton Gregg HEVP, Corp & Med AffairsApr 19Sale100.0140,0004,000,574137,964Apr 21 01:28 PM
MILLIGAN JOHN FPresident and CEOApr 04Option Exercise16.40112,0001,836,2401,170,963Apr 05 07:30 PM
MILLIGAN JOHN FPresident and CEOApr 04Sale94.59112,00010,593,9041,058,963Apr 05 07:30 PM
MARTIN JOHN CExecutive ChairmanApr 01Option Exercise16.40100,0001,639,5004,119,727Apr 05 07:49 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Option Exercise24.912,00049,81063,122Apr 05 06:36 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Sale91.342,000182,68061,122Apr 05 06:36 PM
MARTIN JOHN CExecutive ChairmanApr 01Sale93.24100,0009,323,5074,019,727Apr 05 07:49 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale91.235,000456,158142,090Apr 05 07:45 PM
Alton Gregg HEVP, Corp & Med AffairsMar 14Sale90.005,000450,000147,090Mar 15 07:31 PM
MARTIN JOHN CChairman and CEOMar 01Option Exercise16.40100,0001,639,5004,119,727Mar 03 02:47 PM
MILLIGAN JOHN FPresident, COO and DirectorMar 01Option Exercise16.40112,0001,836,2401,170,963Mar 03 02:54 PM
Carter Paul RutherfordEVP Commercial OpsMar 01Option Exercise24.912,00049,81063,122Mar 03 03:10 PM
MARTIN JOHN CChairman and CEOMar 01Sale88.58100,0008,857,8544,019,727Mar 03 02:47 PM
MILLIGAN JOHN FPresident, COO and DirectorMar 01Sale87.79112,0009,832,9951,058,963Mar 03 02:54 PM
Carter Paul RutherfordEVP Commercial OpsMar 01Sale87.902,000175,80061,122Mar 03 03:10 PM
Washington Robin LEVP, CFOFeb 16Sale90.726,250567,00084,688Feb 18 07:59 PM
MARTIN JOHN CChairman and CEOFeb 01Option Exercise16.40100,0001,639,5004,048,066Feb 03 05:43 PM
Carter Paul RutherfordEVP Commercial OpsFeb 01Option Exercise39.142,00078,27150,783Feb 03 05:42 PM
MARTIN JOHN CChairman and CEOFeb 01Sale83.42100,0008,342,4753,948,066Feb 03 05:43 PM
Carter Paul RutherfordEVP Commercial OpsFeb 01Sale82.322,000164,64048,783Feb 03 05:42 PM
Carter Paul RutherfordEVP Commercial OpsJan 04Option Exercise25.762,00051,52650,783Jan 06 05:08 PM
MARTIN JOHN CChairman and CEOJan 04Option Exercise16.40100,0001,639,5004,048,066Jan 06 05:21 PM
Carter Paul RutherfordEVP Commercial OpsJan 04Sale99.202,000198,40048,783Jan 06 05:08 PM
MARTIN JOHN CChairman and CEOJan 04Sale97.68100,0009,767,7083,948,066Jan 06 05:21 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSODec 15Option Exercise21.9970,0001,539,562197,936Dec 17 03:40 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSODec 15Sale102.4170,0007,168,741127,936Dec 17 03:40 PM
MILLIGAN JOHN FPresident and COODec 07Option Exercise14.50100,0001,450,2501,129,108Dec 09 02:14 PM
MILLIGAN JOHN FPresident and COODec 07Sale103.18100,00010,317,9771,029,108Dec 09 02:14 PM
MARTIN JOHN CChairman and CEODec 01Option Exercise14.50150,0002,175,3754,098,066Dec 03 01:57 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Option Exercise24.3010,000242,950141,422Dec 03 01:57 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Option Exercise26.992,00053,98050,783Dec 03 01:56 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Sale106.0112,0001,272,159129,422Dec 03 01:57 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Sale106.382,000212,76048,783Dec 03 01:56 PM
MARTIN JOHN CChairman and CEODec 01Sale105.82150,00015,873,4673,948,066Dec 03 01:57 PM
Cogan John FrancisDirectorNov 24Option Exercise20.7115,000310,57559,309Nov 25 02:21 PM
Cogan John FrancisDirectorNov 24Sale105.9515,0001,589,19044,309Nov 25 02:21 PM
Whitley Richard JamesDirectorNov 24Sale106.4816917,99530,719Nov 25 02:22 PM
Whitley Richard JamesDirectorNov 23Sale107.182,863306,84530,888Nov 25 02:22 PM
Whitley Richard JamesDirectorNov 20Sale106.995,514589,91733,751Nov 25 02:22 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSONov 16Option Exercise23.7670,0001,662,850235,168Nov 18 12:32 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSONov 16Sale102.6570,0007,185,419165,168Nov 18 12:32 PM
MILLIGAN JOHN FPresident and COONov 09Option Exercise14.50100,0001,450,2501,129,108Nov 12 01:01 PM
MILLIGAN JOHN FPresident and COONov 09Sale107.66100,00010,765,6441,029,108Nov 12 01:01 PM
Washington Robin LEVP, CFONov 05Option Exercise0.006,000033,724Nov 09 05:41 PM
MARTIN JOHN CChairman and CEONov 02Option Exercise14.50150,0002,175,3754,098,066Nov 04 01:23 PM
Alton Gregg HEVP, Corp & Med AffairsNov 02Option Exercise24.3010,000242,950143,422Nov 04 02:41 PM
MARTIN JOHN CChairman and CEONov 02Sale109.42150,00016,413,0263,948,066Nov 04 01:23 PM
Alton Gregg HEVP, Corp & Med AffairsNov 02Sale109.3812,0001,312,507131,422Nov 04 02:41 PM
Washington Robin LEVP, CFONov 02Sale109.466,250684,15088,046Nov 04 04:21 PM
Carter Paul RutherfordEVP Commercial OpsNov 02Sale108.362,000216,71248,783Nov 04 04:27 PM
Cogan John FrancisDirectorOct 27Option Exercise20.7115,000310,57559,309Oct 28 08:13 PM
Cogan John FrancisDirectorOct 27Sale110.0015,0001,650,00044,309Oct 28 08:13 PM
Cogan John FrancisDirectorOct 26Option Exercise20.7115,000310,57559,309Oct 27 03:09 PM
Carter Paul RutherfordEVP Commercial OpsOct 26Sale110.061,500165,09248,783Oct 28 02:51 PM
Cogan John FrancisDirectorOct 26Sale110.0015,0001,650,00044,309Oct 27 03:09 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOOct 15Option Exercise23.6070,0001,652,248235,168Oct 16 05:32 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOOct 15Sale100.0570,0007,003,220165,168Oct 16 05:32 PM
MILLIGAN JOHN FPresident and COOOct 07Option Exercise14.50100,0001,450,2501,129,108Oct 08 02:06 PM
MILLIGAN JOHN FPresident and COOOct 07Sale99.22100,0009,921,5241,029,108Oct 08 02:06 PM
Alton Gregg HEVP, Corp & Med AffairsOct 05Option Exercise24.305,000121,475138,422Oct 07 01:22 PM
Alton Gregg HEVP, Corp & Med AffairsOct 05Sale100.005,000500,000133,422Oct 07 01:22 PM
MARTIN JOHN CChairman and CEOOct 01Option Exercise14.50150,0002,175,3754,098,066Oct 05 01:28 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Option Exercise24.305,000121,475140,422Oct 05 02:13 PM
MARTIN JOHN CChairman and CEOOct 01Sale97.48150,00014,622,2893,948,066Oct 05 01:28 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Sale97.287,000680,930133,422Oct 05 02:13 PM
Carter Paul RutherfordEVP Commercial OpsOct 01Sale98.592,000197,18048,783Oct 05 04:26 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOSep 15Option Exercise23.6070,0001,652,000235,168Sep 17 04:26 PM
Cogan John FrancisDirectorSep 15Option Exercise20.7115,000310,57559,309Sep 17 03:54 PM
Alton Gregg HEVP, Corp & Med AffairsSep 15Option Exercise24.305,000121,475140,422Sep 17 03:55 PM
Alton Gregg HEVP, Corp & Med AffairsSep 15Sale110.005,000550,000135,422Sep 17 03:55 PM
Cogan John FrancisDirectorSep 15Sale110.0015,0001,650,00044,309Sep 17 03:54 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOSep 15Sale110.7070,0007,749,195165,168Sep 17 04:26 PM
MILLIGAN JOHN FPresident and COOSep 08Option Exercise14.50100,0001,450,2501,129,108Sep 10 02:57 PM
MILLIGAN JOHN FPresident and COOSep 08Sale103.39100,00010,338,7301,029,108Sep 10 02:57 PM
Washington Robin LEVP, CFOSep 02Sale102.206,250638,77894,296Sep 03 03:07 PM
Alton Gregg HEVP, Corp & Med AffairsSep 01Option Exercise24.2210,000242,208147,422Sep 03 03:06 PM
Alton Gregg HEVP, Corp & Med AffairsSep 01Sale102.7512,0001,233,008135,422Sep 03 03:06 PM
WILSON GAYLE EDirectorAug 28Option Exercise20.7180,0001,656,400122,769Aug 31 06:17 PM
WILSON GAYLE EDirectorAug 28Sale106.9621,0002,246,160101,769Aug 31 06:17 PM
MARTIN JOHN CChairman and CEOAug 25Sale105.17133,21314,009,8720Aug 26 05:51 PM
Alton Gregg HEVP, Corp & Med AffairsAug 03Option Exercise23.7615,000356,325154,422Aug 04 05:08 PM
Cogan John FrancisDirectorAug 03Option Exercise20.7115,000310,57559,309Aug 04 05:01 PM
MARTIN JOHN CChairman and CEOAug 03Option Exercise14.50150,0002,175,3754,364,492Aug 04 05:07 PM
Carter Paul RutherfordEVP Commercial OpsAug 03Option Exercise26.995,000134,95053,783Aug 04 05:08 PM
Carter Paul RutherfordEVP Commercial OpsAug 03Sale119.185,000595,92048,783Aug 04 05:08 PM
MARTIN JOHN CChairman and CEOAug 03Sale119.18150,00017,876,6194,214,492Aug 04 05:07 PM
Alton Gregg HEVP, Corp & Med AffairsAug 03Sale119.1117,0002,024,870137,422Aug 04 05:08 PM
Cogan John FrancisDirectorAug 03Sale120.0015,0001,800,00044,309Aug 04 05:01 PM
Carter Paul RutherfordEVP Commercial OpsJul 31Option Exercise0.002,500050,132Aug 04 05:00 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJul 15Option Exercise21.5870,0001,510,250235,168Jul 17 03:57 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJul 15Sale118.2066,2617,832,152168,907Jul 17 03:57 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJul 07Sale119.393,739446,400165,168Jul 17 03:57 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Option Exercise26.993,00080,97050,632Jul 06 04:00 PM